Effectiveness and safety analysis of serplulimab-based regimens in patients withHER2-negative advanced gastric cancer from a real-world retrospective study

Efficacy and safety of surufatinib combined with EP regimen and serplulimab in firstline treatment of NEC

Effectiveness and safety of first-line serplulimab in patients with metastatic/locallyadvanced esophageal carcinoma (EC): A real-world study.

Zhang Y, Wei R, Song G, et al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. MAbs. 2024 Jan-Dec;16(1):2419838. doi: 10.1080/19420862.2024.2419838. Epub 2024 Nov 4. PMID: 39497266; PMCID: PMC11540081.